

Please substitute the following claims 1, 5-7, 20, 44, 66, 74 and 76-78 for the pending claims 1, 5-7, 20, 44, 66, 74 and 76-78:

Sub
B17

af

1. (Once amended) A pharmaceutical composition, comprising:
- (a) a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2 in a concentration range of about 0.02 to about 40 mg/ml (w/v);
 - (b) a buffer having a buffering capacity of about pH 5.0 to about pH 8.0 at a concentration range of about 5 mM to about 50 mM;
 - (c) a pharmaceutically acceptable diluent to bring the composition to a designated volume, and
 - (d) a preservative selected from the group consisting of m-cresol, chlorobutanol, and a mixture of methyl paraben and propyl paraben; or a reaction product thereof.

~~7~~
5.

- (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is present in a concentration range of about 0.05 to about 30 mg/ml (w/v).

a
9

~~8~~
6.

- (Once amended) The pharmaceutical composition of claim ~~5~~, wherein said polypeptide is present in a concentration range of about 0.1 to about 20 mg/ml (w/v).

~~7~~

~~9~~
7.

- (Once amended) The pharmaceutical composition of claim ~~6~~, wherein said polypeptide is present in a concentration range of about 0.2 to 4 mg/ml (w/v).

~~8~~

97

A

a10
20. (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

a11
~~48~~
~~44~~. (Once amended) The pharmaceutical composition of claim ~~40~~³⁹, wherein said thickening agent is a water soluble etherified cellulose or a carbomer.

a12
~~63~~
~~66~~. (Once amended) The pharmaceutical composition of claim 1, wherein said polypeptide is present in a concentration range of about 0.01 mg/ml to about 10 mg/ml (w/v).

a13
~~67~~
~~74~~. (Once amended) A pharmaceutical composition comprising:
(a) about 1.0 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;
(b) 20 mM citrate, pH 5-5.5; and
(c) 0.01% polysorbate 80.

a14
Sub
34 76. (Once amended) A pharmaceutical composition comprising:
(a) about 3.3 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of SEQ ID NO:2;
(b) 10 mM sodium citrate
(c) 20 mM sodium chloride;

- all
- (d) 1 mM EDTA;
 - (e) 2% w/v glycine;
 - (f) 0.5% w/v sucrose;
 - (g) water; and
 - (h) pH about 6.2;
- or a reaction product thereof.

72

(Once amended)

The pharmaceutical composition of claim ~~76~~⁷⁰, wherein

over 90% of the water is removed by lyophilization.

all cont.
Sub 351

78.

(Once amended)

A pharmaceutical composition comprising:

- (a) about 1.0 mg/ml of a polypeptide comprising Ser (69) - Ser (208) of

SEQ ID NO:2;

- (b) 10 mM sodium citrate;
- (b) 0.46% hydroxyethylcellulose;
- (c) 7% sucrose;
- (d) 20 mM sodium citrate;
- (e) 20 mM sodium chloride;
- (f) 1 mM EDTA; and
- (g) pH about 6.2;

or reaction products thereof.

Please add the following claims:

⁶⁹~~69~~. (New) The pharmaceutical composition of claim ⁶⁷~~74~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

⁷¹~~80~~. (New) The pharmaceutical composition of claim ⁷⁰~~76~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).

⁷⁴~~81~~. (New) The pharmaceutical composition of claim ⁷³~~78~~, wherein said polypeptide is selected from the group consisting of: (i) Ser (69) - Ser (208) of SEQ ID NO:2; (ii) Ser (69) - Ser (208) of SEQ ID NO:2 with a methionine at the N-terminus; and (iii) a mixture of (i) and (ii).